• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience

  • A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Disease
analgaesia
Drug Name
AZD2066
Generic Name
AZD2066
Sponsor
AstraZeneca
Drug Status
Discontinued
Phase
II
Start Date
Feb 27, 2009
Study Name
D0475C00009
Study Id
D0475C00009
ClinicalTrials.gov ID
NCT00857623
Recruiting Status
Closed
Protocol Status
Not Available
Report
Feb 11, 2010
  • D0475C00009.pdf (145 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013